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Early progression of Krabbe disease in
patients with symptom onset between 0
and 5months
Maria L. Beltran-Quintero1†, Nicholas A. Bascou1†, Michele D. Poe1, David A. Wenger2, Carlos A. Saavedra-Matiz3,
Matthew J. Nichols3 and Maria L. Escolar1*
Abstract
Background: Krabbe disease is a rare neurological disorder caused by a deficiency in the lysosomal enzyme, β-
galactocerebrosidase, resulting in demyelination of the central and peripheral nervous systems. If left without
treatment, Krabbe disease results in progressive neurodegeneration with reduced quality of life and early death. The
purpose of this prospective study was to describe the natural progression of early onset Krabbe disease in a large
cohort of patients.
Methods: Patients with early onset Krabbe disease were prospectively evaluated between 1999 and 2018. Data
sources included diagnostic testing, parent questionnaires, standardized multidisciplinary neurodevelopmental
assessments, and neuroradiological and neurophysiological tests.
Results: We evaluated 88 children with onset between 0 and 5months. Median age of symptom onset was 4
months; median time to diagnosis after onset was 3 months. The most common initial symptoms were irritability,
feeding difficulties, appendicular spasticity, and developmental delay. Other prevalent symptoms included axial
hypotonia, abnormal deep tendon reflexes, constipation, abnormal pupillary response, scoliosis, loss of head control,
and dysautonomia. Results of nerve conduction studies showed that 100% of patients developed peripheral
neuropathy by 6 months of age. Median galactocerebrosidase enzyme activity was 0.05 nmol/h/mg protein. The
median survival was 2 years.
Conclusions: This is the largest prospective natural history study of Krabbe disease. It provides a comprehensive
description of the disease during the first 2 years of life. With recent inclusion of state mandated newborn
screening programs and promising therapeutic interventions, enhancing our understanding of disease progression
in early onset Krabbe disease will be critical for developing treatments, designing clinical trials, and evaluating
outcomes.
Keywords: Krabbe disease, Globoid cell leukodystrophy, Early-infantile, Infantile, Natural history, Newborn screening
Background
Krabbe disease, or globoid cell leukodystrophy (GLD; OMIM
# 245200), is a rare neurological disease with an autosomal
recessive inheritance pattern. Mutations in the GALC gene,
located on chromosome 14, cause a deficiency of the
lysosomal enzyme β-galactocerebrosidase [1]. The resulting
accumulation of the intermediates, galactosylceramide and
galactosylsphingosine (psychosine), leads to severe demyelin-
ation of both the central (CNS) and peripheral (PNS) ner-
vous systems [2–4]. Patients with early onset typically have a
more severe and rapidly progressing phenotype than patients
with later onset. Common symptoms of early onset Krabbe
disease include appendicular spasticity, axial hypotonia, irrit-
ability, severe psychomotor delay or regression, seizures, and
premature death [5–8], whereas clinical features of later on-
set Krabbe disease generally include gradual psychomotor
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regression, development of progressive spastic paraparesis,
and gait abnormalities [9–11].
The incidence of Krabbe disease has been estimated as
one in 100,000 births in the United States and Europe [1,
12]. Historically, patients with Krabbe disease have been di-
vided into subtypes based on their age of onset: early-infant-
ile (0–5months), late-infantile (6–36months), juvenile (3–
16 years), and adult (> 16 years) [13–15]. However, despite
these long-established conventions in nomenclature, few
standardized natural history studies of Krabbe disease have
been conducted to define the phenotypes and the viability of
these arbitrary subtypes remains to be tested by a rigorous,
prospectively designed protocol. Currently, the only treat-
ment available for Krabbe disease is hemopoietic stem cell
transplantation (HSCT). HSCT works by introducing
donor derived cells that migrate to the CNS, providing
compensatory function for defective GALC. HSCT has
been most successful in asymptomatic children by stabiliz-
ing or slowing the progression of CNS demyelination.
Outcomes in patients who are already symptomatic have
been comparatively worse [16–20].
Newborn screening (NBS) for Krabbe disease was intro-
duced in New York State in 2006 and then it has been man-
dated in 9 additional states out of which 6 are currently
screening (NY, OH, MO, KY, IL, TN). The correlations be-
tween GALC activity, psychosine levels, genetic variations,
and clinical presentation are not well established, which can
cause difficulty for parents and physicians when they are
making decisions regarding treatment with HSCT [21–25].
As a result, newborns determined to be at risk of developing
disease must be extensively monitored throughout their early
years of life to identify early clinical markers of disease.
Therefore, knowledge of the natural progression of early on-
set Krabbe disease is needed in order to help families and cli-
nicians make informed treatment decisions as NBS
continues to expand throughout the United States. In
addition, natural history data will be instrumental in evaluat-
ing the efficacy of new treatments, such as gene therapy and
enzyme replacement therapy [26].
While studies describing the clinical presentation of
Krabbe disease have been published to date, most are based
on registry data or retrospective analysis of patient records
and are therefore subject to numerous limitations including
incomplete datasets, inconsistent non-standardized observa-
tions, and small sample sizes. The first case series describing
the clinical presentation was published by Knud Krabbe in
1916 [27]. The article described patients with infantile onset
as having irritability, feeding difficulties and as the disease
progressed, hypertonicity, seizures, loss of vision and hearing,
and early death. Fifty-three years later, the first large cohort
of patients was described by Hagberg et al. [28], which posed
similar findings to those published by Krabbe (1916). In Hag-
berg’s study, clinical evaluations were performed in different
regions of Sweden, and patients were assessed by different
physicians. The study reviewed the records of 90 patients
who were suspected to have the diagnosis of GLD and con-
cluded that 32 of these patients had early-infantile Krabbe
disease. In 2009, Duffner et al. conducted a registry-based
study, which described the average age at onset, initial symp-
toms, survival, and clinical features of Krabbe disease from
responses of 334 parent questionnaires. A follow up study,
focusing specifically on patients with onset between 0 and 6
months, was published in 2011 and expanded its dataset to
include sporadic medical records and parent questionnaires
of 67 patients who were evaluated at multiple sites and by
different physicians. Continuing to expand their use of regis-
try data, Duffner and colleagues published a third study in
2012, which described 45 patients with onset after 6months
of age, including 12 patients with onset between 7 and 12
months, 27 patients with onset between 13months-10 years,
and 6 patients with onset after > 10 years [29, 30]. Our group
recently published a study showing prospective data on pa-
tients with late infantile Krabbe disease, on 35 patients with
Krabbe disease, which together describes in detail 123 pa-
tients [31].
In light of the lack of prospective studies, the purpose of
this research was to longitudinally describe the neurological
progression including signs, symptoms, and neurodevelop-
mental function in children diagnosed with Krabbe disease
and onset between the ages of 0–5months. Patients were
evaluated at a single site, examined by two neurodevelop-
mental pediatricians, and followed throughout the course of
their disease. Multiple standardized tests in all areas of devel-
opment were performed using a prospectively designed
protocol, allowing for internal consistency across patients
and evaluations. Growth parameters were measured at every
visit, and brain magnetic resonance imaging (MRI) and other
neurophysiological analyses were carried out at baseline and
longitudinally, when appropriate. Altogether, this is the lar-
gest prospective study investigating the natural history of
Krabbe patients with onset between 0 and 5months.
Methods
Inclusion/exclusion criteria
From September 1999 to September 2018, 99 Krabbe pa-
tients with onset between 0 and 5months were referred to
the Program for the Study of Neurodevelopment in Rare
Disorders (NDRD) at Children’s Hospital of Pittsburgh
and at University of North Carolina for evaluation, disease
management, and/or enrollment in a natural history
study. Diagnosis was made by measuring GALC activity in
white blood cells or fibroblasts, performed at the Lyso-
somal Diseases Testing Laboratory at Jefferson Medical
College, and were confirmed by GALC gene analysis.
However, since mutation analysis was not used consist-
ently for diagnosis until approximately 2009, most patients
diagnosed prior to 2009 lack genetic data. Children who
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underwent HSCT were censored on the day they began
the transplantation protocol.
Eighty-eight of the 99 patients screened met the inclu-
sion criteria for the prospective protocol. Eleven patients
were excluded either because parents failed to give in-
formed consent (n = 1), the patient was transplanted
prior to their first visit to the NDRD (n = 7), or a full
evaluation could not be completed due to extenuating
circumstances (n = 3). The study was approved by the in-
stitutional review boards of the University of North Car-
olina (IRB-08-0237) and the University of Pittsburgh
(IRB-PRO11050036).
Data collection and analysis
Parents completed a detailed medical history question-
naire, and records received from outside healthcare pro-
viders were reviewed. Each patient was evaluated by a
multidisciplinary team that included a neurodevelop-
mental pediatrician, psychologist, speech pathologist,
audiologist, ophthalmologist, and occupational and
physical therapist. Patients were evaluated longitudinally
to monitor the progression of neurologic disease and
provide recommendations for disease management.
Standardized tests were administered to differentiate
ability level between developmental domains. The transi-
tion to age-appropriate assessment tools was done ac-
cording to the patient’s estimated developmental age,
and outcomes were compared to the norms of typically
developing children [32–37]. Disease-related variables
were acquired from parent questionnaires and patient
medical records. Survival data was obtained by parent
report, internet searches and/or querying the United
States social security death index database. The
Kaplan-Meyer method was used to estimate the median
and overall survival time until November 1, 2018.
In order to track the progression of disease, patients
were divided into age groups based on the age at which
their evaluations occurred. While patients who were
evaluated once only contribute data to a single age
group, others, who have been followed longitudinally,
have multiple evaluations at different ages; therefore,
data from such patients may be included at multiple
time points. See Table 1 for a detailed breakdown of
overall symptom incidence within each age group.
Results
Patient characteristics
We evaluated 88 children with early onset Krabbe dis-
ease (38 boys, 50 girls). Twenty-nine patients were
followed longitudinally (median number of 3 visits). The
remaining 59 children were evaluated only once because
they either underwent HSCT after their baseline visit (n
= 26) or were unable to return for reasons related to
travel or financial difficulties. Thirteen patients were
identified and diagnosed because of a family history of
the disease. For the remaining 75 symptomatic patients,
the median age at diagnosis was 6 months (range: 3–15
months). The median age at which parents first noticed
symptoms was 4 months (range: 0–6 months). The me-
dian delay between symptom onset and diagnosis of
Krabbe disease was 3 months (range: 0.5–13 months). A
total of 146 evaluations were conducted. To examine the
progression of symptoms, the evaluations were grouped
by age into 0–3 (n = 16), 4–6 (n = 28), 7–9 (n = 36), 10–
12 (n = 21), 13–17 (N = 19), 18–23 (n = 11), > 24months
(n = 16) (Table 1).
Prenatal history, diagnosis, and neonatal problems
Of the 88 patients 30 (34%) developed neonatal prob-
lems (jaundice requiring phototherapy, n = 14; breathing
difficulties, n = 4; hypoglycemia, n = 3; feeding difficul-
ties, n = 8; Erb’s palsy, n = 1; irregular heartbeat, n = 6; or
clavicle fracture due to difficult delivery, n = 2).
Thirty-two (36%) infants were delivered by cesarean sec-
tion (frequency in normal US population = 32%).
Initial symptoms
Thirteen of the patients were asymptomatic at the time
of first evaluation. Of the remaining 75 symptomatic pa-
tients, irritability was the most common initial symptom
(n = 41; 54%), followed by feeding difficulties (n = 27;
36%), spasticity (n = 25; 33%), reflux (n = 17; 23%), devel-
opmental delay (n = 25; 33%), poor weight gain (n = 11;
15%) abnormal movements (n = 9; 12%), and decreased
tone (n = 7; 9%). Other initial symptoms included sleep-
ing difficulties (n = 3; 4%), exaggerated startle (n = 4; 5%),
constipation (n = 2; 3%), seizures (n = 1; 1%), spasms (n
= 1), and lethargy (n = 1; 1%). Given the prevalence of
irritability as the most common initial symptom, we
reviewed the onset of this symptom and found that the
median age of onset for irritability was 4months (range:
0–8 months), with 62 (82%) symptomatic patients
presenting with irritability by 8 months of age (Fig. 1).
Growth and survival
Head circumference was within the normal range for
most patients, although 12.5% (n = 11) of patients were
microcephalic at least one-time point. Height and weight
were below the normal range, 28% (n = 25) and 31% (n
= 28), respectively (Fig. 2). Of the 88 patients, 57 are de-
ceased. Results of Kaplan–Meier analysis estimated a
median survival time of 2 years. The earliest death oc-
curred at 6 months. Seventy percent of patients were de-
ceased by 2.5 years of age. Twenty percent of patients
survived until at least 6 years of age (Fig. 3).
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Feeding and gastrointestinal problems
Gastroesophageal reflux, one of the more common fea-
tures of this disease, was present in 17% of patients eval-
uated between 0 and 3months, 62% of patients
evaluated between 4 and 6months old and 84% evalu-
ated between 7 to 9 months. After 10 months of age, the
number of patients with reflux began to decline, likely
due to earlier treatment with Nissen fundoplication sur-
gery and antireflux medications.
One baby (7%) evaluated from 0 to 3 months of age
had feeding problems and difficulty swallowing. How-
ever, the proportion of patients with feeding difficulties
increased to 79% in patients evaluated after 4 months of
age and to 97% of patients after 7 months of age. To
meet nutritional requirements and avoid complications
(e.g., aspiration pneumonia), gastrostomy tube place-
ment with a Nissen fundoplication was recommended.
Seventy percent of children evaluated from 10 to 12
months, and 100% of children who were evaluated after
12 months of age had surgery for gastrostomy tube
placement. Forty-two percent of the patients examined
between 10 and 12months, and 100% of patients
evaluated after 24 months had undergone Nissen fundo-
plication. Gastrointestinal problems were evident in a
large number of patients and included constipation and
diarrhea. Diarrhea was most common in patients evalu-
ated between 4 and 6months of age (25%). Constipation
was noted in only one patient (10%) aged 0–3months;
however, the incidence of constipation became more
common as the disease progressed and was observed in
81% of patients evaluated after 24 months. The need for
suctioning due to the inability to manage secretions was
apparent in 50% of patients evaluated between 7 and 9
months of age; however, by 18 to 23 months of age, the
need for suctioning increased to 91%.
Vision and hearing
Data showed that visual tracking difficulties increased
with disease progression, with 93% of patients evaluated
after 24 months exhibiting severe or complete inability
to visually track. Abnormal eye movements, such as eye
fluttering or jerking, were most common in patients
evaluated between 18 and 23 months of age (78%). Par-
ental concern for vision loss was reported in 9% of
Table 1 Symptom incidence in each age group and cohort as a whole
0-3 months
(n = 16)
4-6 months
(n = 28)
7-9 months
(n = 36)
10-12 months
(n = 21)
13-17 months
(n = 19)
18-23 months
(n = 11)
>24 months
(n = 16)
Symptom N Mean N Mean N Mean N Mean N Mean N Mean N Mean
Reflux 12 17% 26 62% 25 84% 18 61% 8 50% 5 40% 11 45%
Feeding Difficulties or swallowing difficulties 14 7% 28 79% 33 97% 21 90% 16 88% 8 100% 12 100%
Required Suctioning 12 0% 19 11% 28 50% 18 50% 16 81% 11 91% 15 87%
Diarrhea 10 0% 20 25% 20 10% 16 6% 12 0% 6 0% 12 17%
Constipation 10 10% 21 38% 29 59% 18 56% 16 63% 10 70% 16 75%
Visual Tracking Difficulty 14 7% 28 57% 33 58% 19 68% 19 89% 11 64% 16 88%
Jerky eye movements/eye fluttering 13 0% 17 12% 26 27% 19 32% 14 29% 9 78% 13 54%
Nystagmus 12 0% 17 12% 24 0% 18 17% 18 22% 10 20% 14 21%
Hip asymmetry 12 0% 15 7% 25 12% 21 24% 19 47% 11 55% 15 87%
Scoliosis 10 0% 16 13% 28 14% 20 40% 17 65% 10 70% 16 94%
Axial Hypotonia 12 17% 23 65% 30 83% 21 100% 19 100% 11 100% 15 100%
Abnormal DTRs 12 17% 26 88% 31 94% 21 95% 19 100% 11 100% 15 100%
Clasped Thumb/Hand Fisting 12 33% 26 92% 32 94% 20 85% 18 78% 10 60% 15 40%
Appendicular Spasticity 13 8% 24 100% 34 97% 20 90% 19 74% 11 64% 16 75%
Clinical Seizures 10 0% 18 6% 25 8% 20 15% 16 19% 9 33% 15 33%
Staring Episodes 10 0% 17 41% 27 48% 17 41% 14 64% 9 89% 12 92%
Shallow Breathing or Cheyne-Strokes 12 0% 24 17% 30 37% 21 48% 19 79% 11 82% 16 88%
Apneic Episodes 12 0% 17 18% 26 23% 19 32% 17 59% 10 60% 16 63%
Poor Peripheral Perfusion 11 0% 18 0% 24 4% 18 17% 18 44% 10 60% 14 71%
Temperature Instability 14 0% 28 0% 34 6% 21 14% 19 32% 11 55% 16 69%
Abnormal Pupillary Response 11 0% 23 22% 30 43% 19 58% 19 89% 11 100% 14 100%
Displays the incidence of each symptom for patients evaluated between 0 and 3months, 4–6months, 7–9 months, 10–12 months, 13–17 months, 18–23 months,
and ≥ 24 months. Symptoms with incidence > 50% are bolded. N is the number of patients which exhibited the symptoms at that time point. n is the number of
patients that were evaluated for that age range
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patients (median: 16 months; range 4.8–54months).
However, visual evoked potentials (VEP), which were
considered abnormal if the P100 wave was absent, con-
firmed visual pathway neuropathy in the majority of the
sample. Specifically, 60% of patients tested between 0
and 3months had abnormal VEP results, including a 5
days old baby. The percentage of abnormal VEP in-
creased to 100% for patients older than 18months of
age. As for hearing, 2% of parents reported hearing loss.
However, auditory neuropathy, identified through audi-
tory brainstem responses (ABR), revealed that 70% of
patients evaluated between 0 to 3months had abnormal-
ities in waves, I, III, or V, with this proportion quickly
increasing to 100% after 10 months of age.
Orthopedic complications
Fifty-five percent of the children evaluated between 18
and 23 months and 80% of patients evaluated after 24
months presented with hip asymmetry. Scoliosis in-
creased from 40% in patients evaluated between 10 and
12months of age to 94% in patients > 24months.
Neurologic symptoms and signs
More than 77% of children evaluated after 7months lacked
head control and were unable to sit independently. Mobility
became significantly more limited as the disease progressed,
with 80% of patients developing quadriparesis between 10
and 12months of age, and 100% by 24months. Axial hypo-
tonia was observed in 65% of patients aged 4 to 6months,
80% of patients evaluated between 7 to 9months, and
100% in patients evaluated after 10months of age.
Eighty-eight percent of patients evaluated after 4 months
of age had abnormal deep tendon reflexes, which affected
100% of patients by 13months of age. Clasped thumb and
fisting of hands, the most common symptom in patients
evaluated between birth to 3months, began to decrease
after 9months of age. Appendicular spasticity was present
in 100% of patients evaluated between 4 and 6months;
however, appendicular spasticity began to decrease
starting at 7months of age and was only present in 70% of
patients evaluated after 24months of age.
Bulging fontanelle was reported in 3% of patients, one
of which required a ventriculoperitoneal shunt. Staring
episodes were absent in patients younger than 3months
but were present in 83% of patients over the age of 24
months. Clinical seizures were infrequent in children
younger than 10 months of age. After 24 months, 40%
presented with clinical seizures.
Autonomic nervous system involvement
Abnormal sweating was reported in 3% of patients (onset:
5, 12, and 18months). Apneic episodes and changes in
heart rate were first reported in patients older than 5
months, and increased in frequency with disease progres-
sion. Shallow breathing was present in 17% of patients eval-
uated between 4 to 6months, 37% of patients evaluated
between 7 to 9months and increased to 79% in patients
evaluated between 13 and 17months and 88% in patients
> 24months. Of the four (4%) patients who had Cheyne–
Fig. 1 Ages at which common symptoms appear in children with Krabbe disease. The red diamond represents the median age at which the
symptom began. The lines show the minimum and maximum ages that the symptom began
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Fig. 2 Height, weight, and head circumference of boys (blue) and girls (red) with Krabbe disease. Each circle depicts an individual measurement;
lines connecting circles show multiple measurements for an individual child. The gray lines represent standard growth curves (gray lines = 3rd,
5th, 10th, 25th, 50th, 75th, 90th, 95th, and 97th percentiles)
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Stokes respiration, one was 6 months old and three
were > 12 months. Poor peripheral perfusion was noted
in patients evaluated after 8 months of age, with this
sign present in 70% of patients evaluated after 24
months.. Mottling of skin was observed in 28% of pa-
tients evaluated after 8 months. Temperature instability
was reported in children older than 8 months and be-
came more frequent over time (69% in patients older
than 24 months). Results of physical examinations
showed delayed or absent pupillary response in patients
beginning at 4 months, increasing to 89% incidence in
patients evaluated between 13 and 17 months, and
reaching 100% in patients evaluated after 18 months of
age. Although pinpoint pupils were the most common
finding, some patients also presented with dilated pu-
pils or anisocoria.
Neuroradiologic and neurophysiologic testing
Only two patients (14%) evaluated between 0 and 3
months had normal brain MRI scan readings; 100% of
scans after 4months of age were abnormal. Of the 50
EEGs available for analysis, 52% were normal, with gener-
alized slowing evident in 40% of patients. Results of NCV
studies showed that 78% of patients tested between 0 and
3months and 95% between 4 and 6months had abnormal
motor nerve conduction studies. 100% of patients had
abnormal motor nerve conduction by 6months of age.
Abnormal sensory nerve conduction was observed in 93%
of all patients, reaching 100% by 7months of age.
Cerebrospinal fluid and IgG index
Hyperproteinorrachia was detected in 100% patients
who were tested [38, 39]. There were 70 cerebrospinal
fluid (CSF) protein values with a median of 208mg/dl
and ranged from 43 to 594 (Fig. 4). CSF protein levels
were especially high in two patients (> 550 mg/dl); how-
ever, higher protein levels did not correlate with clinical
manifestations, disease severity or genotype. No correl-
ation between gross motor scores or onset of symptoms
with protein levels in CSF was found (p > 0.39).. The
CSF IgG index was normal (< 0.85) in all patients who
were tested. The albumin index, which predicts blood–
brain barrier damage, was elevated in 11 of 30 available
results but did not correlate with disease severity (CSF
IgG index range: 0.006–0.092; median 0.040).
Genetic analysis and enzyme activity
GALC gene analysis was available for 39 patients. Gen-
etic variants, age of onset, and initial symptoms for these
patients are displayed in Table 2.
DNA was extracted from 3-mm dried blood spots (DBS)
using the CASM method [40]. The molecular test was
Fig. 3 Kaplan–Meier curve of overall survival with a median survival of 2 years. The red shaded area represents the 95% confidence interval. The
median survival was 2 years. The x-axis shows age in years and the table below the axis shows the number of patients at risk for an event. The
y-axis indicates the cumulative survival to specific age. Each drop in the curve represents a death. The vertical lines along the curve indicate
that a child was censored while still living (either because they received UCBT or that they were still living at the cutoff date of 11/01/2018).
The cumulative probability is calculated as the product of the interval probabilities up to the age of the event. The denominator for the
calculation of the interval probability is the number of children at risk at the time of the event. Children who are censored while living do not
contribute to the denominator for the next event
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performed using the polymerase chain reaction (PCR)
followed by fluorescence-based (Sanger) sequence analysis
of the 17 coding exons, intron/exon boundaries and the
promoter region of the GALC gene. Testing for g.30kbdel,
the most common infantile-onset GALC pathogenic vari-
ant, and g.7.4del, was performed using gap-PCR and gel
analysis.
All GALC enzyme activity levels were low, with a me-
dian value of 0.05 nmol/h/mg protein (range: 0–0.3
nmol/h/mg protein).
Neurodevelopmental function
Cognitive function, expressive and receptive language, and
motor development were evaluated for each patient. All
children who were evaluated longitudinally showed rapid
developmental regression in multiple domains. Patients
who achieved higher scores on follow up testing than
baseline testing in one or more domains were either ex-
tremely irritable at baseline testing, which subsided after
medication management by the time of their follow up
evaluation or were still asymptomatic at the time of their
baseline evaluation (Figs. 5, 6, and 7).
Cognitive function was assessed using standardized pro-
tocols that tested the ability to listen, solve visual problems,
and perform simple tasks. None of the patients scored
higher than 6months age equivalence at any time point,
and by 6months of age, all patients fell below the normal
range (Fig. 5).
Receptive language was the strongest area of develop-
ment and had the largest number of patients scoring
within the normal range; nevertheless, all patients were
below normal in receptive language by 10months of age.
Most patients scored comparatively worse in expressive
language (Fig. 6).
Gross motor function was the weakest area of develop-
ment. All asymptomatic patients had normal gross motor
function, whereas all symptomatic patients had below
normal function, with most having skills of a 1month or
less age equivalency after 5months (Fig. 7). In regard to
fine motor skills, most symptomatic children scored at a
1-month old level after 8 months, while asymptomatic
children scored in the average or above average range.
Discussion
In this study, we prospectively evaluated a large cohort
of Krabbe patients with onset between 0 and 5months.
Unlike earlier studies, such as Duffer et al. (2011) and
Hagberg et al. (1969), the current study implemented a
prospective longitudinal design, in which patients were
evaluated at a single site by two neurodevelopmental
pediatricians working with a multidisciplinary team
using standardized tests. To our knowledge, this is the
largest single site prospective study characterizing the
natural history of early onset Krabbe disease. Results of
the study reveal a disease course, in which the majority
of patients are minimally symptomatic or asymptomatic
from 0 to 3 months of age. However, results of MRI, and
NCVs revealed evidence of disease much earlier [41, 42].
Nevertheless, once clinical symptoms emerged, disease
progression was rapid and severe.
Fig. 4 CSF protein levels. CSF protein levels were plotted against patient age. The red diamonds represent the CSF protein level at a single point
in time. Levels from the same individual, but at different points in time, are connected by red lines. The blue shaded area represents 95%
variability of CSF protein level of the normal population by age
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Table 2 Genotype/Phenotype correlation for patients (n = 39) with available data
Patient Allele 1 Allele 2 Age at
Onset
(Months)
Earliest Clinical Symptoms
DNA Protein DNA Protein
1 c.1586C>T p.Thr529Met#2 c.1586C>T p.Thr529Met#2 4 Feeding difficulty; Irritability
2 g.30Kbdel c.1158del10 p.Met387Phefs*? 0 Irritability
3 g.30Kbdel c.622-1G>T Missplicing NA Asymptomatic
4 c.242_243dupGA p.Ile82Argfs*? c.1700A>C p.Tyr567Ser#1 4 Developmental delay; Spasticity
5 c.379 C>T p.Arg127* c.864G>A p. Trp288* 4 Spasticity; Feeding difficulty; Irritability
6 g.30Kbdel g.30Kbdel 3 Feeding difficulty
7 g.30Kbdel c.430delA p.Ile144Leufs*? 3 Spasticity; Feeding difficulty
8 c.628A>T p.Arg210* c.1895T>C p.Leu632Pro#1 3.5 Spasticity; Feeding difficulty; Irritability
9 c.884A>T p.Asn295Ile#1 c.884A>T p.Asn295Ile#1 1 Feeding difficulty
10 g.30Kbdel c.544G>A p.Glu198Lys 4 Irritability
11 g.30Kbdel c.658C>T p.Arg220*#1 1.5 Feeding difficulty; Irritability; Reflux
12 c.749T>C p.Ile250Thr c.1586C>T p.Thr529Met 4 Feeding difficulty; Reflux
13 c.1884delA p.Lys628Asnfs*7#2 g.5.78 Mb
del
3 Feeding difficulty; Irritability; Reflux
14 c.155delG p.Gly52Alafs*? c.155delG p.Gly52Alafs*? 3 Feeding difficulty; Irritability; Reflux
15 g.30Kbdel c.620delA p.Lys191fs*? 2.5 Feeding difficulty; Developmental delay
16 c.430delA p.Ile144Leufs*? c.628A>T p.Arg210* 5 Spasticity; Irritability; Constipation
17 g.30Kbdel c.1657G>A p.Gly553Arg 4 Spasticity; Irritability; Developmental delay
18 g.30Kbdel g.30Kbdel 2 Irritability; Developmental delay; Poor weight gain; Spasms
19 c.583-6T>A#1 Missplicing g.7.4Kbdel#1 5 Feeding difficulty; Developmental delay; Hypotonia
20 c.2056T>C p.*686Glnext*42#1 c.430DelA p.Ile144Leufs*?#1 3 Developmental delay
21 c.316G>A p.Gly106Arg c.521delA p.Tyr158Leufs*3 4 Irritability
22 c.967G>T p.Gly323Trp c.1472delA p.Lys491Argfs*62 4 Irritability; Reflux
23 c.489G>A p.Trp163*#1 c.489G>T p.Trp163Cys#1 5 Spasticity; Irritability; Developmental Delay
24 c.387C>G p.Tyr129* c.1814dupA p.Tyr605fs*1 5 Spasticity; Developmental delay
25 c.533G>A p.Trp178*#1 c.1468T>A p.Tyr490Asn#1 NA Asymptomatic
26 g.30Kbdel c.674C>A p.Ala225Glu NA Asymptomatic
27 g.30Kbdel g.30Kbdel 3 Feeding difficulty; Hypotonia
28 g.30Kbdel c.1004A>G p.Tyr335Cys#1 3 Feeding difficulty; Spasticity
29 g.30Kbdel c.1004A>G p.Tyr335Cys#1 4 Spasticity; Irritability; Developmental Delay; Hypotonia
30 g.30Kbdel c.490C>A p.Pro164Thr 5 Spasticity; Developmental delay
31 g.30Kbdel g.30Kbdel 4 Spasticity; Developmental delay
32 c.1700A>C p.Tyr567Ser#1 c.1158del10 p.Met387Phefs*? 2 Reflux
33 g.30Kbdel c.1543G>A p.Glu515Lys#1 5 Irritability; Reflux
34 c.764C>A p.Pro255His#1 c.1591C>T p.Arg531Cys#1 1 Spasticity
35 g.30Kbdel c.1004A>G p.Tyr335Cys#1 5 Feeding difficulty; Spasticity; Developmental delay
36 g.30Kbdel g.30Kbdel 5 Spasticity; Irritability
37 g.30Kbdel g.30Kbdel 5 Feeding difficulty; Developmental delay
38 g.30Kbdel c.1766dupA p.Tyr605fs*1#1 4 Developmental delay; Hypotonia
39 c.869G>A p.Arg290His c.1480T>C p.Phe494Leu 4 Development delay: irritability
Patients 3, 25 and 26 were transplanted before symptoms. Variants are reported using Human Genome Variation Society (HGVS) nomenclature. Reference
sequences NP_000144.2 (Protein) and NM_000153.3 (cDNA nucleotide). The most common infantile-onset allele, g.30Kbdel (c.1161 + 6555_*9573del), was always
detected in ‘cis’ with the pseudodeficiency variant p.Arg184Cys (c.550C > T). #variants detected in ‘cis’ with the pseudodeficieny alleles p.Ile562Thr (c.1685 T > C)#1
or p.Asp248Asn (c.742G > A)#2
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Given the rapid progression of disease following onset, it
is imperative that physicians can identify early clinical
markers of disease. Overall, we found irritability, clasped
thumb and hand fisting to be the most common indicators
of disease in patients aged 0–3months of age. Although re-
flux was prevalent in these young patients, it did not exceed
the incidence of reflux in the normal age-matched
population until after 7months of age [43, 44]. Interestingly
100% of NCV were abnormal by 6months of age. For pa-
tients aged 4–6months and patients aged 7–9months, the
most prevalent markers of disease were irritability, clasped
thumbs and hand fisting, appendicular spasticity, feeding
and swallowing difficulty, and abnormal DTR’s. In patients
aged 10–12months, axial hypotonia was evidenced. For
Fig. 5 Cognitive development in children with Krabbe disease. Age-equivalent scores (i.e., developmental age) are graphed against actual age for
cognitive development. Evaluations performed on the same individuals, longitudinally, are connected by blue lines. The gray lines from left to
right represent the approximate 97.5th, 50th and 2.5th percentiles of development for normal age-matched controls
a b
Fig. 6 Language development in children with Krabbe disease. Age-equivalent scores (i.e., developmental age) are graphed against actual age for
(a) receptive and (b) expressive language. Evaluations performed on the same individuals, longitudinally, are connected by blue lines. The gray
lines from left to right represent the approximate 97.5th, 50th and 2.5th percentiles of development for normal age-matched controls. Because of
limitations in the Mullen Scales of Early Learning, the lowest AE a patient could score is 1 month
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patients 13–17months of age, markers such as staring
episodes, shallow breathing, visual tracking difficulties, and
abnormal pupillary response began to evolve. However, it
should be noted that a large decrease in the incidence of
appendicular spasticity was observed in patients > 12
months, likely attributable to progression in peripheral
nerve disease resulting in severe muscle weakness. Patients
over the age of 18months, developed in addition of eye
fluttering, severe constipation, orthopedic complication (i.e.
scoliosis and hip subluxation), and dysautonomia (i.e.
temperature instability, non-pitting edema, and poor
peripheral perfusion), all of which become more prevalent
in children more than 2 years of age.
Despite the severe and rapid disease progression
throughout the first 2 years of life, our group has previ-
ously demonstrated that HSCT treatment in babies within
the first 2 months of life (when they are mostly asymp-
tomatic) is associated with essentially normal receptive
language skills, continuous gains in cognitive skills, ex-
tended survival, and improvement or stabilization in brain
atrophy, as shown by brain MRI scans [16, 20]. Unfortu-
nately, babies become symptomatic within 4months after
birth but are not diagnosed in a timely manner. The ma-
jority are ineligible for HSCT because their disease may
already be too advanced [16, 18, 45]. Thus, earlier diagno-
sis will allow more patients to benefit from treatments
that substantially reduce disease progression and improve
their quality of life. Although extreme irritability appears
early and is the most common initial symptom of disease,
irritability due to colic is also typical in the normal
pediatric population beginning around 4months of life,
making it common for physicians and caretakers to
initially disregard the concern. However, unlike colic, irrit-
ability in Krabbe disease is much more severe and
constant throughout the day [46]. Therefore, we strongly
recommend that severely irritable babies undergo a feed-
ing evaluation, and a neurological examination. For babies
who present with abnormal muscle tone, slow feeding,
swallowing difficulties, and/or reflux, we recommend a
brain MRI. Abnormal findings should prompt subsequent
enzyme activity and genetic analysis [31].
Although recognizing the early signs of infantile Krabbe
disease frequently delays diagnosis and prevents effective
HSCT, NBS will allow for the early diagnosis and treat-
ment. NBS was initiated in New York on August 7, 2006,
started in Missouri in August 2012, Kentucky and Ohio in
2016, Illinois and Tennessee since 2017. Legislation to
screen for Krabbe disease has since been passed in the
states of Louisiana, New Jersey, New Mexico, and Penn-
sylvania. Nevertheless, natural history data will remain
important, as NBS is not available in many states and our
understanding of the genetic and biochemical markers of
Krabbe disease are still limited. While GALC enzyme
activity has been used to diagnose the disease, the correl-
ation between enzyme activity and phenotype remains
poor. Increased psychosine levels in dry blood spots (DBS)
are currently being used as a second-tier biomarker that
can accurately predict early disease onset [25]. However,
further work is necessary to understand the relationship
between natural disease progression, pathogenic variants
in the GALC gene, enzyme activity, and psychosine levels.
Establishing correlations between the genetic variations,
psychosine levels and phenotype will require a very large
database. This is due to more than 200 known pathogenic,
likely pathogenic or variants of unknown significance
(VUS) and the multiple pseudodeficiency variants that in-
fluence enzyme activity (haplotype effect) when in ‘cis’
with a ‘mild’ allele [47, 48]. Thus, until these databases are
a b
Fig. 7 Motor development in children with Krabbe disease. Age-equivalent scores (i.e., developmental age) are graphed against actual age for (a)
gross and (b) fine motor. Evaluations performed on the same individuals, longitudinally, are connected by blue lines. The gray lines from left to
right represent the approximate 97.5th, 50th and 2.5th percentiles of development for normal age-matched controls
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further developed, NBS legislation is expanded, and NBS
methodologies are refined, awareness and knowledge of
the presenting symptoms and clinical manifestations of
early onset Krabbe disease will remain the primary source
of early diagnosis and referral for future clinical trials.
Limitations of our study include restricted accessibility
to some outside medical records and difficulty recruiting
patients for longitudinal follow up once they became too
sick to travel. Because a portion of the information was
collected via a parent questionnaire, some data is subject
to recall bias. In addition, many children underwent
HSCT after their first evaluation and therefore could not
be followed longitudinally. Because certain symptoms
were treated following baseline visits (i.e. reflux, feeding
and swallowing difficulties, excretions, diarrhea, and con-
stipation) the incidence of these symptoms in our popula-
tions may be slightly altered in respect to the disease’s true
natural history. Despite these limitations, the prospective
design and standardized protocols for physical and neuro-
developmental evaluations make this study uniquely
powerful in providing a comprehensive description of the
natural history of patients with early onset Krabbe disease.
Conclusion
This study characterized the disease progression in Krabbe
patients with onset between 0 and 5months of age. Patients
presented with extreme irritability and feeding difficulties.
However, evidence of disease was apparent on MRI, NCVs,
ABRs and VEPs well before patients became clinically
symptomatic, which is especially important in asymptom-
atic children with low enzyme level and likely pathogenic
variants or VUS that are being monitored for disease onset
after screening positive through NBS programs. Because of
the haplotype effect, reporting the pseudodeficiency allele is
important. As the disease progressed, patients developed
appendicular spasticity and abnormal DTR’s, followed by
axial hypotonia, visual tracking difficulties, staring episodes,
quadriparesis, scoliosis, and dysautonomia. An improved
understanding regarding the clinical course of this rapidly
progressing disease is essential to facilitating early diagnosis,
assisting in the management and treatment of afflicted
patients, and designing successful clinical trials.
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